Acasti Pharma, Inc (ACST)

[CoolG73]

will take a look Watson, a bit early for summer .

I am focused right now on ACST to see how this P3 will unfold.

lots of drama going on in the last week. waiting patiently for the T1 numbers and my expectations are HTG delta between 29 and 31% at least(which is great compared to VAscepa 33% which accounted for 10% of Placebo increase) + achieving a meaningful delta in HDL, Non-HDL , VLDL (beating VAscepa)

keeping in mind that HTG can fluctuate 25% over 12 weeks in normal patients (and even more in severe HTG patients), achieving a delta around 30% is a great achievement, add to this unmet (by other competitors) improvement in the other lipid management measurements makes Capre the go to drug